Search the Newsreel

LivaNova (LIVN) Q2 2026 Earnings Call Transcript

LivaNova reported record Q2 2026 revenue of $390.6 million and adjusted diluted EPS of $1.26, exceeding prior-year figures, driven by strong demand in Cardiopulmonary and Epilepsy segments. The company raised its full-year 2026 revenue guidance to 8%-9% growth and adjusted diluted EPS guidance to …

LivaNova PLC (LIVN) employee stock rights lead to 2,675-share sale

LivaNova PLC has reported a planned sale of 2,675 shares of common stock, stemming from the exercise of employee stock appreciation rights. The transaction, valued at $209,942.40, is scheduled for August 11, 2026, and will be executed through Merrill Lynch as a broker-assisted cashless …

Price-Driven Insight from (LIVN) for Rule-Based Strategy

This article provides a price-driven insight into Livanova Plc (NASDAQ: LIVN) for rule-based trading strategies. It highlights weak near-term sentiment challenging long-term strength, with support being tested. The analysis identifies an exceptional 28.8:1 risk-reward setup targeting an 8.4% gain against 0.3% risk, and outlines …

LivaNova (LIVN) Is Down 7.6% After Swinging Back To Profitability In Q2 2026 - What's Changed

LivaNova (LIVN) reported a significant turnaround in Q2 2026, swinging back to profitability with US$108.57 million in net income and US$390.59 million in sales. This improvement was driven by strong first-half sales of US$752.85 million and a shift from a prior-year loss, strengthening the …

Price to earnings forward of LivaNova Plc – FWB:LIA

This article provides a brief overview of LivaNova Plc's forward price-to-earnings ratio on the Frankfurt Stock Exchange (FWB:LIA). It highlights that the market is currently closed with no trades, and the content is primarily focused on the financial data of the company. The page …

LivaNova (LIVN) Rebounds On Earnings As The Bull Case Points To More Upside

LivaNova PLC (LIVN) Stock News Today

LivaNova PLC (LIVN) (Q2 2026) Earnings Call Highlights: Record Revenue and EPS, Raised Guidance ...

LivaNova PLC (LIVN) reported record revenue of $391 million and adjusted EPS of $1.26 for Q2 2026, driven by strong growth in both Cardiopulmonary and Epilepsy segments. The company raised its full-year 2026 revenue guidance to 8%-9% growth and adjusted EPS guidance to $4.30-$4.40, …

FMR LLC (LIVN) discloses 5.8% LivaNova stake in Schedule 13G filing

FMR LLC has filed a Schedule 13G, disclosing a beneficial ownership of 5.8% in LivaNova PLC (LIVN) common stock, amounting to 3,210,395.27 shares as of June 30, 2026. Both FMR LLC and Abigail P. Johnson reported this stake, with FMR LLC holding sole voting …

LivaNova PLC Stock 12‑Month Price Target Raised to $88.78, Implies 4% Upside

LivaNova PLC (LIVN) has seen its average 12-month price target increased from $86.78 to $88.78 by 9 analysts, with individual forecasts ranging from $75 to $95. This new target suggests a potential upside of approximately 4% from its closing price on August 4. The …

LivaNova Sees Solid Demand in Both Cardiopulmonary and Neuromodulation

LivaNova Plans for Early 2027 Launch of Aura6000 for Obstructive Sleep Apnea

LivaNova, a medical-device firm, plans an early 2027 launch for its Aura6000 device designed to treat obstructive sleep apnea. The company employs an innovation strategy focused on differentiated products and strong commercialization through salesforce relationships, similar to larger competitors. This strategy aims to create …

LivaNova (LIVN) Stock Drops As Cash Flow Concerns Cut Through Profit Surge

LivaNova Q2 Earnings & Revenues Beat Estimates, '26 Outlook Raised

LivaNova (NASDAQ:LIVN) Releases Quarterly Earnings Results, Beats Estimates By $0.17 EPS

Earnings call transcript: LivaNova tops Q2 2026 estimates and lifts outlook

LivaNova PLC 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:LIVN) 2026-08-05

LivaNova PLC (NASDAQ: LIVN) has released its Q2 2026 earnings call presentation. The company reported an EPS of $1.26, beating estimates by $0.17, and revenue of $390.60 million, a 10.81% year-over-year increase, beating estimates by $10.02 million. This presentation provides details on their financial …

LivaNova (LIVN) Reports Q2 Earnings: What Key Metrics Have to Say

LivaNova (LIVN) reported strong Q2 2026 earnings, with revenue of $390.6 million and EPS of $1.26, surpassing Wall Street expectations. The company exceeded consensus estimates for net sales in Neuromodulation, Cardiopulmonary, and Other segments. Despite the positive results, LivaNova's stock performance over the past …

LivaNova PLC (LIVN) Hits Fresh High: Is There Still Room to Run?

A strong stock as of late has been LivaNova (LIVN). Shares have been marching higher, with the stock up 2.1% over the past month. The stock hit a new 52-week high of $85.76 in the previous session. LivaNova has gained 38.7% since the start …

LivaNova exceeds second-quarter forecasts and increases 2026 outlook

Graph showing growth ©Adobe Stock Images LivaNova (NASDAQ:LIVN) reported second-quarter results that surpassed Wall Street expectations, prompting the medical technology company to raise its earnings and revenue guidance for the full year. The stronger performance helped lift the shares around 1.3% in after-hours trading. …

Earnings Flash (LIVN) LivaNova PLC Reports Q2 Revenue $390.6M, vs. FactSet Est of $380.5M

LivaNova PLC (LIVN) announced Q2 revenue of $390.6 million, surpassing the FactSet estimate of $380.5 million. The company also reported Q2 adjusted EPS of $1.26 per share, exceeding the FactSet estimate of $1.09, and raised its fiscal 2026 adjusted EPS outlook to a range …

LivaNova plc (LIVN) Tops Q2 EPS by 17c ; Offers Guidance

LivaNova plc (LIVN) exceeded analyst expectations for its Q2 earnings, reporting an EPS of $1.26 against an estimated $1.09, and revenue of $390.6 million compared to the $380.57 million consensus. The company also provided optimistic guidance for FY2026 EPS, projecting $4.30-$4.40, which is above …

LivaNova Q2 Revenue Rises 10.8 Percent To $390.6 Million

LivaNova PLC: LivaNova Reports Second-Quarter 2026 Results; Raises Full-Year 2026 Revenue and Adjusted Diluted EPS Guidance

LivaNova PLC reported strong second-quarter 2026 results, with reported revenue growth of 10.8% and constant-currency growth of 9.8%. The company raised its full-year 2026 revenue and adjusted diluted earnings per share guidance, citing sustained performance in its Cardiopulmonary and Neuromodulation businesses. LivaNova also announced …

LivaNova (NASDAQ:LIVN) Updates FY 2026 Earnings Guidance

LivaNova (Nasdaq: LIVN) Q2 2026 nets $108.6M income on higher sales

LivaNova (LIVN) Q2 Earnings and Revenues Beat Estimates

LivaNova (NASDAQ: LIVN) posts strong Q2 growth and raises 2026 guidance

LivaNova PLC stock hits 52-week high at 85.28 USD By Investing.com

LivaNova PLC stock reached a new 52-week high of $85.28, reflecting a significant upward trend with a 92.84% 1-year total return. The company, with a market capitalization of $4.68 billion, is considered slightly undervalued according to InvestingPro, which also highlights its low P/E ratio …

LivaNova PLC (LIVN) Stock Analysis: Navigating Growth in Healthcare with a 14.3% Revenue Surge

(LIVN) Price Dynamics and Execution-Aware Positioning

This article analyzes Livanova Plc (NASDAQ: LIVN) price dynamics, identifying a near-term strong sentiment transitioning to mid-term neutrality and long-term positive bias. It highlights an exceptional 26.2:1 risk-reward short setup and provides institutional trading strategies for different risk profiles, including position trading, momentum breakout, …

LivaNova PLC (LIVN) Financial Health: Profitability & Balance Sheet Analysis

LivaNova PLC (LIVN) has a robust financial status with a current financial score of 7.86, ranking 54 out of 199 in its industry. The company reported a significant year-over-year revenue increase of 14.33% and a net profit increase of 106.81%, demonstrating high operating efficiency. …

LivaNova PLC (LIVN) Institutional Confidence

This article analyzes the institutional confidence in LivaNova PLC (LIVN), reporting its current institutional shareholding score as 10.00, which ranks 1st in the Healthcare Equipment & Supplies industry. Institutional shareholding has increased by 3.56% quarter-over-quarter, with HOTCHKIS & WILEY identified as the largest institutional …